Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8578954 | 0.84 | ESR2 (0.53) | ESR2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31700659 | 0.80 | LIMK2 (0.49) | ALDH1A1HPGDSMN1; SMN2USP30CYP2C9 | |
| SCHEMBL3670111 | 0.79 | ESR2 (0.63) | ESR2ALDH1A1HDAC1HDAC8HDAC6 | |
| SCHEMBL21628489 | 0.79 | HPGD (0.71) | ALDH1A1HPGDSMN1; SMN2USP30HDAC1 | |
| SCHEMBL14403055 | 0.78 | ESR2 (0.78) | ESR2HDAC1HDAC8HDAC6PDE4A | |
| SCHEMBL7888980 | 0.77 | ESR2 (0.61) | ESR2ALDH1A1HDAC1HDAC8HDAC6 | |
| SCHEMBL247920 | 0.77 | ESR2 (0.61) | ESR2ALDH1A1HDAC1HDAC8HDAC6 | |
| SCHEMBL22047765 | 0.77 | KDM4E (0.49) | ESR2SMN1; SMN2HSD11B1PDE4APDE4B | |
| SCHEMBL19993940 | 0.77 | ESR2 (0.56) | ESR2ALDH1A1HPGDSMN1; SMN2HDAC1 | |
| SCHEMBL614371 | 0.77 | ESR2 (0.56) | ESR2ALDH1A1HPGDSMN1; SMN2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912498-B1 | 4(4-OXOCYCLOHEXYL) BENZAMIDES AS INTERMEDIATE PRODUCTS FOR MEDICAMENTS | MERCK PATENT GMBH (DE) | 2004-05-12 | — | — | EP | claimed |
| US-6177594-B1 | IN SYNTHESIZING A DRUG COMPOUND THE TITLE COMPOUND IS REDUCED BY REACTION WITH A COMPLEX METAL HYDRIDE; PREPARATION OF THE BENZAMIDE INCLUDES AMINATION OF THE CORRESPONDING ACYL HALIDE, CARBOXY OR ESTER WITH A SECONDARY AMINE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2001-01-23 | — | — | US | claimed |
| EP-0912498-A1 | 4(4-OXOCYCLOHEXYL) BENZAMIDES AS INTERMEDIATE PRODUCTS FOR MEDICAMENTS | MERCK PATENT GmbH (DE) | 1999-05-06 | — | — | EP | claimed |
| WO-1998001420-A1 | 4(4-OXOCYCLOHEXYL) BENZAMIDES AS INTERMEDIATE PRODUCTS FOR MEDICAMENTS | MERCK PATENT GMBH (DE) | 1998-01-15 | — | — | WO | claimed |
| CN-109952300-B | 5-or 8-substituted imidazo [1,5-a ] pyridines | 百济神州有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2021-01-05 | — | — | US | disclosed |
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2021-01-05 | — | — | US | disclosed |
| EP-3515914-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BeiGene, Ltd. (KY) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018054365-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018054365-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2018-03-29 | — | — | WO | disclosed |
| CN-102153539-B | As the 3-amino-pyrrolidine derivatives of chemokine receptor modulators | Because of C1-esteraseremmer-N parent corporation (US) | 2016-01-13 | — | — | CN | disclosed |
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | disclosed |
| CN-1741994-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP (US) | 2006-03-01 | — | — | CN | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-0912498-B1 | 4(4-OXOCYCLOHEXYL) BENZAMIDES AS INTERMEDIATE PRODUCTS FOR MEDICAMENTS | MERCK PATENT GMBH (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-6177594-B1 | IN SYNTHESIZING A DRUG COMPOUND THE TITLE COMPOUND IS REDUCED BY REACTION WITH A COMPLEX METAL HYDRIDE; PREPARATION OF THE BENZAMIDE INCLUDES AMINATION OF THE CORRESPONDING ACYL HALIDE, CARBOXY OR ESTER WITH A SECONDARY AMINE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2001-01-23 | — | — | US | disclosed |
| WO-1998015522-A2 | METHOD FOR PREPARING TRANS-4-(4-AMINOMETHYLPHENYL) CYCLOHEXANOL DERIVATIVES | SYNTHELABO (FR) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | IDO1, TPH1, IDO2 | ESR2 4151/4885ALDH1A1 621/4885HPGD 135/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | ESR2 902/4885ALDH1A1 2501/4885HPGD 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.